
According to data presented at the 2021 American Society of Hematology Annual Meeting, an updated International Prognosis Scoring System (IPSS) for myelodysplastic syndromes (MDS) that incorporates gene mutations (IPSS-M) led to improved discrimination compared with the revised IPSS (IPSS-R). The IPSS-M, which considers clinical, cytogenetic, and genetic parameters, reclassified nearly half of patients studied.
The IPSS-M score was built as a weighted sum of prognostic variables. The model consisted of:
- hemoglobin, platelets, and bone marrow blasts
- IPSS-R cytogenetic category
- 22 binary features derived from the presence of mutations in 21 predictive genes
- one feature representing the number of mutations from a group of 17 additional genes
Investigators applied scaling so that a score of 0 represented an average patient; scores of –1, 1, or 2 corresponded to half-, double-, or four-fold risk compared with an average patient.
Researchers characterized 9,339 driver mutations or short indels involving 124 genes from 2,957 patients (discovery cohort). These patients had less than 20% blasts and white blood cell count below 13×109/L. Median follow-up was 3.8 years.
They then conducted correlative analyses between genetic alterations and clinical outcomes. Results were validated in an independent cohort of 718 patients.
According to the investigators, the IPSS-M resulted in improved discrimination compared with the IPSS-R for leukemia-free survival, overall survival, and leukemic transformation. Specifically, they found a 5-point increase in C-index for each endpoint in the discovery cohort and an increase of 3.4, 1.5, and 4.9 points in the validation cohort.
Based on score cutoffs, researchers established a six-risk category schema: very-low (14%), low (32%), moderate-low (11%), moderate-high (11%), high (11%), and very-high (18%). From very-low to very-high, the median leukemia-free survival was 9.7, 6.0, 4.1, 2.3, 1.7, and 0.75 years, respectively.
By merging the moderate-low and moderate-high categories to moderate, the researchers compared stratification of the IPSS-R with the IPSS-M. The IPSS-M resulted in restratification of 46% of patients. The majority (74%) were upstaged and 26% were downstaged.